Skip to content

13F-HR filed by Camber Capital Management LP

Camber Capital Management LP filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-15, with 32 holding rows worth $2,814,977,620.

Accession
0001654954-25-005756
Filed
2025-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2025

A holdings report, 32 entries on the cover page, a total value of $2,814,977,620 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,814,977,620 with VALUE read as dollars as filed, 13F file number 028-13745. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPY78462F103SHS1,500,000$839,085,000dollars as filedput
ZIMMER BIOMET HOLDINGS INC COM98956P102Stock2,250,000$254,655,000dollars as filed
BAXTER INTL INC071813109COM5,750,000$196,822,500dollars as filed
HUMANA INC COM444859102Stock725,000$191,835,000dollars as filed
Pfizer Inc.717081103COM6,800,000$172,312,000dollars as filedcall
SPDR SER TR78464A870S&P BIOTECH2,000,000$162,200,000dollars as filedput
CVS Health Corporation126650100COM2,250,000$152,437,500dollars as filed
GLOBUS MED INC CL A379577208Stock1,250,000$91,500,000dollars as filed
PTC THERAPEUTICS INC69366J200COM1,500,000$76,440,000dollars as filed
Cigna Corporation125523100COM200,000$65,800,000dollars as filed
VIATRIS INC COM92556V106Stock7,500,000$65,325,000dollars as filed
Pfizer Inc.717081103COM2,500,000$63,350,000dollars as filed
QIAGEN NVN72482206COM SHS1,400,000$56,210,000dollars as filed
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR350,000$54,551,000dollars as filed
SAREPTA THERAPEUTICS INC803607100COM800,000$51,056,000dollars as filed
BROOKDALE SR LIVING INC112463104COM6,250,000$39,125,000dollars as filed
GSK PLC SPONSORED ADR37733W204ADR1,000,000$38,740,000dollars as filedcall
BIOMARIN PHARMACEUTICAL INC09061G101COM500,000$35,345,000dollars as filed
CONCENTRA GROUP HOLDINGS PAR20603L102COMMON STOCK1,600,000$34,720,000dollars as filed
EVOLENT HEALTH INC CL A30050B101Stock3,000,000$28,410,000dollars as filed
IONIS PHARMACEUTICALS INC COM462222100Stock725,000$21,873,250dollars as filed
MYRIAD GENETICS INC62855J104COM2,350,000$20,844,500dollars as filed
ZIMVIE INC98888T107COM1,885,000$20,358,000dollars as filed
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock441,000$17,229,870dollars as filed
DENALI THERAPEUTICS INC COM24823R105Stock1,250,000$16,993,750dollars as filed
ANAPTYSBIO INC032724106COM750,000$13,942,500dollars as filed
THERAVANCE BIOPHARMA INCG8807B106COM1,000,000$8,930,000dollars as filed
10X GENOMICS INC CL A COM88025U109Stock1,000,000$8,730,000dollars as filed
INOGEN INC45780L104COM975,000$6,951,750dollars as filed
STRUCTURE THERAPEUTICS INC COMP86366E106EQUITY300,000$5,193,000dollars as filed
ORASURE TECHNOLOGIES INC68554V108COM900,000$3,033,000dollars as filed
GENMAB A/S372303206Ordinary Shares, nominal value DKK 1 per share50,000$979,000dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001654954-25-005756this filing2025-05-15acceptance time not in the bulk data set